Identifying immune system markers to predict treatment response in ovarian cancer
Defining tumor and blood-based immunogenomic signatures predicting response to immunotherapy in ovarian cancer
This study is looking at how certain genes and immune system markers can help doctors figure out which ovarian cancer patients are most likely to benefit from immunotherapy, so they can create more personalized treatment plans just for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10949078 on NIH RePORTER |
What this research studies
This research investigates how specific genetic and immune system markers can predict which ovarian cancer patients will respond best to immunotherapy. By analyzing tumor and blood samples, the study aims to identify biomarkers that indicate the likelihood of a positive response to treatments that activate the immune system. The approach focuses on understanding the regulatory networks that influence T-cell activation, which are crucial for effective immunotherapy. Patients may have their immune profiles assessed to tailor treatment plans more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are ovarian cancer patients who are considering or currently undergoing immunotherapy.
Not a fit: Patients with early-stage ovarian cancer or those not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective immunotherapy treatments for ovarian cancer patients.
How similar studies have performed: Other research has shown promise in using genetic and immune markers to predict treatment responses in various cancers, indicating that this approach may be viable.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Monson, Kelsey R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Monson, Kelsey R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.